Kenvue Inc. (NYSE:KVUE) Stake Decreased by Blackhawk Capital Partners LLC.

Blackhawk Capital Partners LLC. lessened its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 26.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 54,561 shares of the company's stock after selling 20,023 shares during the period. Blackhawk Capital Partners LLC.'s holdings in Kenvue were worth $1,308,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the business. Norges Bank bought a new stake in Kenvue during the fourth quarter worth approximately $521,348,000. Starboard Value LP bought a new stake in Kenvue during the fourth quarter worth approximately $467,864,000. Franklin Resources Inc. raised its holdings in Kenvue by 61.5% during the fourth quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock worth $912,059,000 after purchasing an additional 16,269,721 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in Kenvue by 12.3% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company's stock worth $2,085,070,000 after purchasing an additional 10,682,003 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in Kenvue by 3.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company's stock worth $5,249,665,000 after purchasing an additional 8,211,748 shares in the last quarter. Institutional investors own 97.64% of the company's stock.

Kenvue Trading Down 0.6%

Kenvue stock opened at $20.92 on Tuesday. The company's fifty day simple moving average is $22.57 and its 200-day simple moving average is $22.32. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.63. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $25.17. The stock has a market cap of $40.14 billion, a P/E ratio of 38.04, a P/E/G ratio of 3.27 and a beta of 0.83.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.23 by $0.01. Kenvue had a net margin of 6.90% and a return on equity of 20.87%. The business had revenue of $3.74 billion for the quarter, compared to analysts' expectations of $3.69 billion. During the same period in the previous year, the company posted $0.28 EPS. Kenvue's revenue was down 3.9% on a year-over-year basis. As a group, sell-side analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th were issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.92%. The ex-dividend date of this dividend was Wednesday, May 14th. Kenvue's dividend payout ratio is currently 149.09%.

Analysts Set New Price Targets

KVUE has been the topic of several recent analyst reports. Citigroup reissued a "neutral" rating on shares of Kenvue in a report on Friday, June 13th. Barclays lifted their price target on shares of Kenvue from $22.00 to $23.00 and gave the stock an "equal weight" rating in a research report on Monday, May 12th. Evercore ISI began coverage on shares of Kenvue in a research report on Monday, March 24th. They issued an "in-line" rating and a $25.00 price target on the stock. UBS Group lifted their price target on shares of Kenvue from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Friday, May 9th. Finally, Redburn Atlantic started coverage on shares of Kenvue in a research report on Thursday, April 10th. They issued a "neutral" rating and a $23.50 price target on the stock. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, Kenvue currently has a consensus rating of "Hold" and an average target price of $25.33.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.